Incyte [INCY] vs Alnylam [ALNY] Detailed Stock Comparison
Incyte
NASDAQ
Loading...
Alnylam
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Incyte wins in 12 metrics, Alnylam wins in 6 metrics, with 0 ties. Incyte appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Incyte | Alnylam | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 19.29 | -198.40 | Alnylam |
| Price-to-Book Ratio | 3.80 | 224.74 | Incyte |
| Debt-to-Equity Ratio | 1.02 | 1,093.31 | Incyte |
| PEG Ratio | 13.29 | -352.40 | Alnylam |
| EV/EBITDA | 12.33 | -454.67 | Alnylam |
| Profit Margin (TTM) | 18.99% | -12.96% | Incyte |
| Operating Margin (TTM) | 25.63% | -2.09% | Incyte |
| EBITDA Margin (TTM) | 25.63% | N/A | N/A |
| Return on Equity | 24.30% | -257.83% | Incyte |
| Return on Assets (TTM) | 11.52% | -2.63% | Incyte |
| Free Cash Flow (TTM) | $235.17M | $-42.59M | Incyte |
| 1-Year Return | 39.83% | 67.35% | Alnylam |
| Price-to-Sales Ratio (TTM) | 3.48 | 22.89 | Incyte |
| Enterprise Value | $13.08B | $56.24B | Alnylam |
| EV/Revenue Ratio | 2.85 | 22.84 | Incyte |
| Gross Profit Margin (TTM) | 93.52% | 81.52% | Incyte |
| Revenue per Share (TTM) | $24 | $19 | Incyte |
| Earnings per Share (Diluted) | $4.23 | $-2.45 | Incyte |
| Beta (Stock Volatility) | 0.72 | 0.25 | Alnylam |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Incyte vs Alnylam Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Incyte | 0.88% | 10.88% | 27.36% | 38.50% | 21.96% | 25.01% |
| Alnylam | 1.40% | 2.27% | 44.29% | 58.40% | 79.56% | 92.15% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Incyte | 39.83% | 16.61% | -7.64% | -16.67% | 611.29% | 1,125.95% |
| Alnylam | 67.35% | 107.86% | 228.63% | 349.58% | 3,169.56% | 4,753.08% |
Performance & Financial Health Analysis: Incyte vs Alnylam
| Metric | INCY | ALNY |
|---|---|---|
| Market Information | ||
| Market Cap | $15.94B | $56.35B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,842,946 | 1,618,830 |
| 90 Day Avg. Volume | 1,681,152 | 1,133,040 |
| Last Close | $86.92 | $448.91 |
| 52 Week Range | $53.56 - $87.06 | $205.87 - $449.52 |
| % from 52W High | -0.16% | -0.14% |
| All-Time High | $153.15 (Mar 13, 2017) | $449.52 (Aug 15, 2025) |
| % from All-Time High | -43.25% | -0.14% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.17% | 0.17% |
| Quarterly Earnings Growth | 0.16% | 0.17% |
| Financial Health | ||
| Profit Margin (TTM) | 0.19% | -0.13% |
| Operating Margin (TTM) | 0.26% | -0.02% |
| Return on Equity (TTM) | 0.24% | -2.58% |
| Debt to Equity (MRQ) | 1.02 | 1,093.31 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $21.49 | $1.91 |
| Cash per Share (MRQ) | $12.40 | $21.80 |
| Operating Cash Flow (TTM) | $1.00B | $-15,539,000 |
| Levered Free Cash Flow (TTM) | $680.37M | $85.71M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Incyte vs Alnylam
| Metric | INCY | ALNY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 19.29 | -198.40 |
| Forward P/E | 13.29 | -352.40 |
| PEG Ratio | 13.29 | -352.40 |
| Price to Sales (TTM) | 3.48 | 22.89 |
| Price to Book (MRQ) | 3.80 | 224.74 |
| Market Capitalization | ||
| Market Capitalization | $15.94B | $56.35B |
| Enterprise Value | $13.08B | $56.24B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.85 | 22.84 |
| Enterprise to EBITDA | 12.33 | -454.67 |
| Risk & Other Metrics | ||
| Beta | 0.72 | 0.25 |
| Book Value per Share (MRQ) | $21.49 | $1.91 |
Financial Statements Comparison: Incyte vs Alnylam
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | INCY | ALNY |
|---|---|---|
| Revenue/Sales | $1.05B | $773.69M |
| Cost of Goods Sold | $73.20M | $142.95M |
| Gross Profit | $979.70M | $630.74M |
| Research & Development | $437.28M | $323.62M |
| Operating Income (EBIT) | $216.72M | $-16.20M |
| EBITDA | $270.13M | $35.44M |
| Pre-Tax Income | $234.19M | $-35.36M |
| Income Tax | $75.99M | $30.92M |
| Net Income (Profit) | $158.20M | $-66.28M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | INCY | ALNY |
|---|---|---|
| Cash & Equivalents | $1.94B | $1.02B |
| Total Current Assets | $3.51B | $3.27B |
| Total Current Liabilities | $1.72B | $1.08B |
| Long-Term Debt | $32.64M | $1.26B |
| Total Shareholders Equity | $3.67B | $115.44M |
| Retained Earnings | $-914.68M | $-7.35B |
| Property, Plant & Equipment | $287.08M | $695.92M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | INCY | ALNY |
|---|---|---|
| Operating Cash Flow | $251.93M | $-145.39M |
| Capital Expenditures | N/A | $-8.97M |
| Free Cash Flow | $262.90M | $-127.28M |
| Debt Repayment | $-1.09M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | INCY | ALNY |
|---|---|---|
| Shares Short | 7.42M | 3.24M |
| Short Ratio | 4.42 | 3.08 |
| Short % of Float | 0.05% | 0.03% |
| Average Daily Volume (10 Day) | 1,842,946 | 1,618,830 |
| Average Daily Volume (90 Day) | 1,681,152 | 1,133,040 |
| Shares Outstanding | 193.43M | 129.29M |
| Float Shares | 162.69M | 126.15M |
| % Held by Insiders | 0.02% | 0.04% |
| % Held by Institutions | 1.01% | 0.97% |
Dividend Analysis & Yield Comparison: Incyte vs Alnylam
| Metric | INCY | ALNY |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |